🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Dihydrexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 1 small molecule active

    1 trial

  2. Disulfiram

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 1 small molecule completed

    1 trial

  3. Divalproex Sodium Extended-release 250mg

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule active

    1 trial

  4. Docetaxel

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  5. Dociparstat sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  6. Dofetilide

    BRIGHT MINDS BIOSCIENCES INC.

    Drug-induced QT Prolongation

    phase 1 small molecule completed

    1 trial

  7. Domvanalimab

    Arcus Biosciences

    Solid Tumor, Unspecified, Adult

    phase 1 small molecule completed

    1 trial

  8. Dose escalation trial of BNT152+153 in patients with cancer

    BioNTech SE

    Various solid tumors that are metastatic or unresectable

    phase 1 other active

    1 trial

  9. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Disorder

    phase 1 small molecule terminated

    1 trial

  10. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  11. Dronabinol Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 1 small molecule active

    1 trial

  12. Drug A (Blinded Drug)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule on hold

    1 trial

  13. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  14. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  15. EBC-129

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumours

    phase 1 small molecule active

    1 trial

  16. ECHO (Empowering Our Community & Health Outcomes)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 1 other terminated

    1 trial

  17. ECIG liquid vehicles

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Exposure

    phase 1 other completed

    1 trial

  18. ENA-001

    BRIGHT MINDS BIOSCIENCES INC.

    Respiratory Depression

    phase 1 small molecule active

    1 trial

  19. ET1402L1-ARTEMIS™ T cells -IV

    AEON Biopharma

    Hepatocellular Carcinoma

    phase 1 mab completed

    1 trial

  20. ETC-159

    BRIGHT MINDS BIOSCIENCES INC.

    With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  21. ETC-1907206

    BRIGHT MINDS BIOSCIENCES INC.

    Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 1 small molecule terminated

    1 trial

  22. ETC-1922159

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumors

    phase 1 small molecule active

    1 trial

  23. ETR028, ETR029, [ETR028 + ETR029] or HCBT

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Pain

    phase 1 small molecule active

    1 trial

  24. Effect of NBI-921355 on corticospinal excitability in healthy participants

    NEUROCRINE BIOSCIENCES INC

    Epilepsy

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources